Rituximab: A promising therapy in systemic lupus erythematosus

Autoimmunity Reviews

Volumn 5, Issue 1, 2006, Pages 18-24

  Thatayatikom, Akaluck ^a   White, Andrew J ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

B cell depletion; CD20; Rituximab; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; CD20 ANTIGEN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ABSCESS; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTHRALGIA; ARTHRITIS; B LYMPHOCYTE; BELL PALSY; BLOOD TRANSFUSION REACTION; CANDIDIASIS; CELL SUBPOPULATION; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; FOLLICULITIS; GASTROENTERITIS; HERPES ZOSTER; HOMEOSTASIS; HUMAN; HYPERSENSITIVITY REACTION; INFLAMMATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL DOCUMENTATION; MUCOSA INFLAMMATION; NECROTIZING FASCIITIS; NEUROLOGIC DISEASE; ONSET AGE; PANCREATITIS; PAROTID GLAND; PATIENT CARE; PEDIATRICS; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THIGH; TINEA PEDIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VASCULITIS;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; APOPTOSIS; B-LYMPHOCYTES; CLINICAL TRIALS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; T-LYMPHOCYTES;

EID: 28744446703     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2005.05.006     Document Type: Review

References (20)

1. P.E. Lipsky Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity Nat Immunol 2 2001 764 766
2. R.W. Hoffman T cells in the pathogenesis of systemic lupus erythematosus Clin Immunol 113 2004 4 13
3. V. Pascual, J. Banchereau, and A.K. Palucka The central role of dendritic cells and interferon-alpha in SLE Curr Opin Rheumatol 15 2003 546 556
4. J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, I. Sanz, and J. Rosenblatt The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus Arthritis Rheum 48 2003 455 459
5. G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, and P. Colombat Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 2002 754 758
6. J.H. Anolik, J. Barnard, A. Cappione, A.E. Pugh-Bernard, R.E. Felgar, and R.J. Looney Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus Arthritis Rheum 50 2004 3580 3590
7. P.P. Sfikakis, J.N. Boletis, S. Lionaki, V. Vigklis, K.G. Fragiadaki, and A. Iniotaki Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40ligand: an open-label trial Arthritis Rheum 52 2005 501 513
8. S. Perrotta, F. Locatelli, A. La Manna, L. Cennamo, P. De Stefano, and B. Nobili Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus Br J Haematol 116 2002 465 467
9. M.J. Leandro, J.C. Edwards, G. Cambridge, M.R. Ehrenstein, and D.A. Isenberg An open study of B lymphocyte depletion in systemic lupus erythematosus Arthritis Rheum 46 2002 2673 2677
10. C. Kneitz, M. Wilhelm, and H.P. Tony Effective B cell depletion with rituximab in the treatment of autoimmune diseases Immunobiology 206 2002 519 527
11. K. Saito, M. Nawata, S. Nakayamada, M. Tokunaga, J. Tsukada, and Y. Tanaka Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement Lupus 12 2003 798 800
12. G.P. Fra, G.C. Avanzi, and E. Bartoli Remission of refractory lupus nephritis with a protocol including rituximab Lupus 12 2003 783 787
13. R. Weide, J. Heymanns, A. Pandorf, and H. Koppler Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy Lupus 12 2003 779 782
14. R. ten Cate, F.J. Smiers, R.G. Bredius, A.C. Lankester, L.W. van Suijlekom-Smit, and T.W. Huizinga Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus Rheumatology (Oxford) 43 2004 244
15. R.J. Looney, J.H. Anolik, D. Campbell, R.E. Felgar, F. Young, and L.J. Arend B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis Rheum 50 2004 2580 2589
16. R.F. van Vollenhoven, I. Gunnarsson, E. Welin-Henriksso, B. Sundelin, A. Osterborg, and S.H. Jacobson Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone Scand J Rheumatol 33 2004 423 427
17. M. Tokunaga, K. Fujii, K. Saito, S. Nakayamada, S. Tsujimura, and M. Nawata Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab Rheumatology (Oxford) 44 2005 176 182
18. M. Edelbauer, T. Jungraithmayr, and L.B. Zimmerhackl Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression Pediatr Nephrol 20 2005 811 813
19. A. Thatayatikom, A.R. French, and A.J. White Rituximab therapy in refractory systemic lupus erythematosus: therapeutic response in four cases Abstract presented at the 2005 Spring School of Systemic Autoimmune diseases 2005 (March) Clinical Immunology Society Santa Fe
20. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, and D.R. Close Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2004 2572 2581